

Video Article

DNA Fingerprinting of *Mycobacterium leprae* Strains Using Variable Number Tandem Repeat (VNTR) - Fragment Length Analysis (FLA)

Ronald W. Jensen¹, Jason Rivest¹, Wei Li¹, Varalakshmi Vissa¹¹Department of Microbiology, Immunology and Pathology, Colorado State UniversityCorrespondence to: Varalakshmi Vissa at vvissa@colostate.eduURL: <https://www.jove.com/video/3104>DOI: [doi:10.3791/3104](https://doi.org/10.3791/3104)

Keywords: Immunology, Issue 53, Mycobacterium leprae, leprosy, biopsy, STR, VNTR, PCR, fragment length analysis

Date Published: 7/15/2011

Citation: Jensen, R.W., Rivest, J., Li, W., Vissa, V. DNA Fingerprinting of *Mycobacterium leprae* Strains Using Variable Number Tandem Repeat (VNTR) - Fragment Length Analysis (FLA). *J. Vis. Exp.* (53), e3104, doi:10.3791/3104 (2011).

Abstract

The study of the transmission of leprosy is particularly difficult since the causative agent, *Mycobacterium leprae*, cannot be cultured in the laboratory. The only sources of the bacteria are leprosy patients, and experimentally infected armadillos and nude mice. Thus, many of the methods used in modern epidemiology are not available for the study of leprosy. Despite an extensive global drug treatment program for leprosy implemented by the WHO¹, leprosy remains endemic in many countries with approximately 250,000 new cases each year.² The entire *M. leprae* genome has been mapped^{3,4} and many loci have been identified that have repeated segments of 2 or more base pairs (called micro- and minisatellites).⁵ Clinical strains of *M. leprae* may vary in the number of tandem repeated segments (short tandem repeats, STR) at many of these loci.^{5,6,7} Variable number tandem repeat (VNTR)⁵ analysis has been used to distinguish different strains of the leprosy bacilli. Some of the loci appear to be more stable than others, showing less variation in repeat numbers, while others seem to change more rapidly, sometimes in the same patient. While the variability of certain VNTRs has brought up questions regarding their suitability for strain typing^{7,8,9}, the emerging data suggest that analyzing multiple loci, which are diverse in their stability, can be used as a valuable epidemiological tool. Multiple locus VNTR analysis (MLVA)¹⁰ has been used to study leprosy evolution and transmission in several countries including China^{11,12}, Malawi⁸, the Philippines^{10,13}, and Brazil¹⁴. MLVA involves multiple steps. First, bacterial DNA is extracted along with host tissue DNA from clinical biopsies or slit skin smears (SSS).¹⁰ The desired loci are then amplified from the extracted DNA via polymerase chain reaction (PCR). Fluorescently-labeled primers for 4-5 different loci are used per reaction, with 18 loci being amplified in a total of four reactions.¹⁰ The PCR products may be subjected to agarose gel electrophoresis to verify the presence of the desired DNA segments, and then submitted for fluorescent fragment length analysis (FLA) using capillary electrophoresis. DNA from armadillo passaged bacteria with a known number of repeat copies for each locus is used as a positive control. The FLA chromatograms are then examined using *Peak Scanner* software and fragment length is converted to number of VNTR copies (allele). Finally, the VNTR haplotypes are analyzed for patterns, and when combined with patient clinical data can be used to track distribution of strain types.

Video Link

The video component of this article can be found at <https://www.jove.com/video/3104/>

Protocol

The purpose of this video article is to provide an overview of the work flow along with data format and interpretation for researchers that may just be starting this type of work (**Figure 1**). It includes demonstration of techniques, simplified protocols and practical tips described in previously published works.^{5,10}

General Work Flow and Laboratory Facilities:

There should be at least 3 separate work areas for this kind of research. The laboratory should have 1) a pre-PCR area with a PCR hood (clean air box or isolated work area) for primer preparation (dilution, aliquot preparation and mixing), 2) a separate bio-safe cabinet for handling and addition of DNA to the PCR mixtures, and 3) a post-PCR work area for preparing and loading gels and for preparing samples for FLA. Primers and DNA samples should be kept in separate freezers and refrigerators. Primer contamination is one of the chief and most persistent problems in laboratory work of this type. Pipettes used for primers and PCR mixes should NOT be used for DNA. There should be separate sets of pipettes for the pre-PCR, PCR and post-PCR work areas. Generally, one researcher can process 12-18 samples in a 12-24 hour period using standard laboratory equipment.

Before beginning each phase of work:

- Wear a lab coat and gloves. Gloves should be worn any time biological samples, primers, DNA and ethidium bromide are being handled. Change gloves frequently.
- Work in a PCR cabinet hood, biosafety cabinet or clean work area.
- Use a fresh bench paper or pad.
- Set up waste receptacles suitable for liquids and pipette tips.

- Wipe down with the inside of the PCR hood and pipettes with 70% ethanol.
- Subject pipettes and work area to UV light for 15 minutes before PCR set up. (Ultraviolet light crosslinks surface DNA contaminants.)
- Always use aerosol prevention pipette tips for materials containing DNA, primers and PCR reagents.
- Centrifuge any tubes/strips/plates containing liquid before opening to prevent aerosol escape and cross-contamination by handling.

1. *M. leprae* DNA preparation

Clinical samples containing *M. leprae* are obtained from leprosy patients who visit skin clinics. Routine diagnostic samples may be skin punch biopsies, slit skin smears or nasal swabs. Generally, punch biopsies or slits skin smears are the best for molecular epidemiology because they are clean and contain sufficient amounts of *M. leprae*. Use of these materials for research must be approved according to institutional guidelines.

1. Preserve biopsy or slit skin smear samples in a screw-cap vial with 1 ml of 70% ethanol.
2. Centrifuge each sample in a variable speed bench-top centrifuge at 12,000 x g for 15 minutes.
3. Remove the supernatant and place it in a microcentrifuge tube. If necessary, it may be useful to re-centrifuge these samples and recover additional tissue or DNA later.
4. Add 500 μ l of phosphate buffered saline (PBS) to the tissue samples and soak for 1 hour to exchange residual ethanol preservative and rehydrate the sample.
5. Centrifuge the samples in a bench-top centrifuge at 12,000 x g for 20 minutes. Discard the PBS solution in a waste container partially filled with disinfectant solution.
6. Extract bacterial DNA using the Qiagen DNEasy Blood and Tissue kit following the guidelines prescribed.
7. Extracted DNA should be aliquoted into 4 vials. Store 2 aliquots at -80°C for future use if/when reproducibility of test results is required or when new technologies become available. Store one aliquot at -20°C and one at 4°C for more immediate use.
8. It is prudent to prepare an 'extraction blank' along with the tissue samples. The blank is subjected to all the same treatments outlined above but is performed without tissue. PCR the extraction blank along with the patient samples to guarantee that the operator's extraction technique is correct and that reagents are free of DNA contamination.

2. Primer preparation

1. Primers for the loci for which there are the most extensive strain type data are listed in **Table 1**. Four or 5 primers are combined for multiplex PCR. One primer for each locus carries a 5' fluorescent chemical tag that will be detected during capillary electrophoresis fragment length analysis (FLA).
2. For each multiplex PCR combination, the tagged primer and corresponding reverse primer for each locus are combined in separate Eppendorf tubes: forward primers in one tube, reverse in another. Stock primers are prepared as 100 μ M solutions (**Figure 2a**), a portion of which is diluted 10x to a concentration of 10 μ M using TE (1x Tris-EDTA, pH 8.0). Remaining aliquots of the 100 μ M primer solutions are stored at -20°C for later use.
3. Equal quantities of each 10 μ M primer are mixed resulting in 2 μ M final concentrations of each primer. When the primer combinations are added to the PCR mixture (**Table 3**), the final concentration of each primer drops to 0.2 μ M.

When the combined primers are added to the PCR mixtures (**Table 3**), final concentrations drop to 0.2 μ M each.

3. Amplifying bacterial DNA using multiplex PCR

1. PCR Setup
 - Record the number of samples that will be used and prepare a worksheet with the required reagents and their volumes before collecting the necessary plastics and other materials.
 - Label the sterile tubes/strips/plates to be used for the PCR with sample numbers. Remember to include positive and negative controls.
2. Wipe down the thermocycler with a cleaning solution (such as Decon ELIMINase) and program it according to **Table 2**. Change gloves after cleaning and before handling primers and other reagents.
3. Prepare PCR Mastermix according to **Table 3** and label the PCR tubes/strips/plate with the primer combination and sample numbers to be used.
4. Aliquot 18 μ l of Mastermix to each labeled PCR sample tube or well. Change gloves.
5. Wipe down a separate bio-safety cabinet and pipettes with 70% ethanol to help clean and disinfect the work area and tools, then subject the work area and pipettes to UV light for 15 minutes to cross-link any DNA contaminants. Change gloves.
6. In the clean bio-safe cabinet, add 2 μ l of the DNA template to the Mastermix in each PCR tube/plate well to acquire a total volume of 20 μ l (**Figure 2b**). Use aerosol prevention pipette tips for all liquid materials.
7. Centrifuge the PCR tubes/strips/plates briefly to mix contents.
8. Place the sample tubes/strips/plate in the thermocycler and start the PCR program.
9. When the program is complete, remove the products from the thermocycler and store at 4°C until electrophoresis.

4. Gel electrophoresis of PCR products

**This protocol has been standard for many years and is an optional step that can be employed if confirmation of PCR products is desired prior to sending them for FLA.*

1. In a separate post-PCR work area, prepare a 2% agarose gel. Use 2.0g agarose powder/100ml of 1x TBE (Tris/Borate/EDTA) buffer solution in a flask. Heat the mixture for about 1.5-2 minutes in a microwave oven. Swirl the contents, heating again if necessary to dissolve the agarose. Cool slightly and pour the gel in a form using a comb with enough wells for the samples.

2. Remove the PCR products from 4°C and centrifuge for about 30 seconds.
3. Mix 2-5µl of PCR product with 0.5-1µl of 5x or 6x gel loading buffer (Loading buffer is available from various companies, or may be mixed up in the lab. Recipes are available online.)
4. Load the wells of the gel with the 6µl sample/loading buffer mix. Add a molecular ladder to one well (preferably a 20 bp ladder).
5. Run the gel at 100V for approximately 90 minutes.
6. Soak the gel in ethidium bromide solution for 15-30 minutes, then in ultrapure distilled water for an equal amount of time.
7. Image the gel while UV light is applied. There should be a band for each of the 4-5 DNA segments in the combination (**Figure 3**).
8. Dispose of the gel in accordance with the institution's hazardous materials policy. Ethidium bromide solution can be used multiple times before proper disposal.

5. Preparing samples for fragment length analysis (FLA)

1. In a clean Eppendorf tube, prepare a master mixture containing 12µl of Hi-Di formamide solution from a fresh aliquot and 0.3µl of GeneScan -500 LIZ sizing standard (both from Applied BioSystems) for each sample to be tested. (Hi-Di formamide chemically denatures the DNA strands prior to capillary electrophoresis, eliminating the need for heating.) Using a 96-well optical quality reaction plate, aliquot 12.3µl of the formamide-LIZ mix to each well being used for samples and set the plate aside.
2. Make a plate map for your records indicating which DNA sample is in each well (**Figure 4a**).
3. Using tubes/strips or a 96-well plate, add 1µl of PCR product (from **Part 3**) to 59µl of PCR quality water creating a 1:60 dilution of the PCR product. Dilutions may be adjusted based on signal strength from the FLA data or brightness of gel bands. Even lower concentrations of DNA may be sufficient (1:120 or 1:180).
4. Add 1µl of the diluted PCR product to the correct well in the plate containing the formamide-LIZ mixture.
5. Speed and efficiency can be greatly enhanced if the PCR was also done in a 96-well plate. One can simply line up 3 such plates in sequence: Plate 1 with PCR products, Plate 2 with sterile water for the dilution of the PCR products, and Plate 3 with formamide and sizing ladder for fragment length analysis. A multichannel pipette allows for a quick process of FLA preparation.

Sample Analysis via Genetic Analyzer

6. Calibrate the Genetic Analyzer to detect the applied fluorophores per the manufacturer's instruction. Be sure to use a dye-set that includes LIZ.
7. Replenish the water rinse containers and add new Running Buffer with EDTA (1x) (Applied BioSystems) to buffer chambers.
8. Add a pre-slit silicon septum to the plate and place the plate in the designed holding tray. Press the 'Tray' button on the Genetic Analyzer to bring the autosampler forward. Place tray onto autosampler and close the door to the Genetic Analyzer.
9. Create or import a spreadsheet for the analysis. Importable files have a .plt extension and are in tab-delimited format. Files can be modified in Excel (Microsoft) or similar programs.
10. The samples are injected into the capillary (50-cm length, POP-7 polymer) by applying an injection voltage of 1.6 kV for 15 s. The capillary electrophoresis runs at a voltage of 15 kV at 60°C for 1800 seconds. The entire process takes about 45 minutes.
11. Once a run is complete, the data for each sample analyzed are converted into files with a .fsa extension and placed in a plate file folder (**Figure 4b**). Each data file is roughly 100 kB in size and can be stored on a flash drive or zipped and emailed. Data files can be viewed using suitable software, such as ABI's GeneMapper or Peak Scanner.

6. Analysis of fragment length results

1. Analysis of the data from fluorescent capillary electrophoresis requires special software. If such software is not available, go the *Applied BioSystems* website and download *Peak Scanner*. The software is free and works quite well. <https://products.appliedbiosystems.com/ab/en/US/adirect/ab?cmd=catNavigate2&catID=603624>
2. Open *Peak Scanner* and 'Start New Project' followed by 'Add Files'. Load the selected .fsa data files into the program, including the positive and negative controls.
3. Select (highlight) and "analyze" all loaded files. Be sure each sample is set to "Size Standard: GS500(-250) and Analysis Method: Sizing Default-pp. Press 'Analyze'.
4. Examine the size in base pairs of each colored peak produced by the DNA fragments in the samples.
5. Record each peak size value in base pairs and compare it to the positive control peak.
6. Peaks in the positive control samples should compare favorably with the numbers of base pairs and corresponding numbers of tandem repeats listed in **Tables 4-7**.
7. Determine how many short tandem repeat segments are present in each sample allele by comparison with the positive control. We use NHDP63 which has been sequenced for the number of VNTR copies at each locus being examined.⁴
8. Enter the recorded data into a spreadsheet for comparative and/or mathematical analyses. VNTR 'fingerprints' or haplotypes, are strings of alleles at defined loci that are characteristic of a *M. leprae* strain.

7. Representative Results

Gel electrophoresis of the PCR products will hopefully produce a band for each locus in the primer combination (**Figure 3**). In **Figure 3**, there are 2 sections to the gel: the top section has Combination 1 PCR samples and the lower portion Combination 2 samples. Each section contains a 20 base pair molecular ladder, followed by PCR products obtained from 8 patient samples. Combination 1 also has a negative control and finally a positive control (NHDP63 strain). (The controls for combination 2 were on a different gel.) Note that most samples clearly display 5 bands, 1 for each locus in the combination. In some cases, bands may be too close together to appear as separate loci resulting in the appearance of only 4 bands.

Expected amplicon sizes are listed in **Table 1**. Our laboratory uses NHDP63 strain of *M. leprae* as a positive control. Two types of repeat segments have been studied: microsatellite loci (with 1-5 base repeats) and minisatellite loci (with segments greater than 5 base pairs repeated multiple times).⁵

Interpretation of the data files from capillary electrophoresis relies on 2 standards: an internal DNA fragment sizing standard called GeneScan-500LIZ (ABI) and an external positive control sample of amplified bacterial DNA.

The FLA chromatograms, viewed using *Peak Scanner* software, can be seen in **Figures 5a, 5b and 6**.

Peak Scanner provides data on amplicon size (x-axis in base pairs) and signal strength (y-axis). (**Figure 5b**) Additional data on peak area, etc. are also available, although the size and peak height values are most important. Peaks less than 100 units in height are usually considered too weak a signal to be reliable.

Figure 6 compares the positive control (NHDP63) and two patient samples, showing a variation in the number of tandem repeats at locus (GTA)9. In the positive control, the sequence (GTA) is repeated 10 times. The NHDP63 VNTR and amplicon size were verified through gene sequencing. Patient 4's PCR amplicon is 3 bp smaller than the positive control indicating there are only 9 repeat units, while Patient 6 has an amplicon that is 3 bp larger than NHDP63 revealing 11 repeats of (GTA). Patient 2 had low bacterial index (BI) with little or no DNA PCR replication, therefore no FLA signal.

Difficulty in FLA data interpretation sometimes occurs as a result of 'stuttering'. During the PCR reaction, the DNA polymerase may produce fragments that are 1 or more repeats longer or shorter than the source allele. These are usually recognized as peaks of lower height surrounding the main peak. They will be 'on the ladder' that is, the correct number of base pairs of the repeat segment larger or smaller than the principal peak. The result is a family of peaks of the same color. **Figure 7** shows this with locus (TA)10.

Another difficulty sometimes encountered with FLA involves '+A' or 'A-tailing', in which the DNA polymerase adds a single base [usually adenine (A)] to the 3' end of the copied DNA segment. This shows up in FLA as a peak to the right of a main or stutter peak that is 1 base pair larger than the adjacent peak as shown in **Figure 8**. It should not be confused with a main or stutter peak. A principal peak and its A-tail are considered a single species. The A-tail does not alter the number of VNTR repeats. (Some DNA polymerase kits are designed to specifically promote A-tailing in order to reduce this confounding effect. Promoting complete A-tailing tends to produce a single peak rather than a pair of peaks.)

The DNA extraction and PCR products contain both *M. leprae* and human DNA, however with the exception of (TA)18, the primers are specific enough that they only amplify the bacterial DNA, and there is little or no human DNA amplification. (TA)18 often produces a peak at 242 base pairs that is from human DNA and is not seen in armadillo passaged DNA samples (**Figure 9**).

The shelf life of primers is generally good provided they are kept at -20°C, only removed for immediate use, and then stored at 4°C until consumed. Primers should be stable at 4°C for 1-2 weeks. Even though making primer combinations for PCR is somewhat time consuming, it is recommended that only enough primer combination for immediate use be prepared. Primer combinations seem to degrade somewhat when stored for prolonged periods.

TE should be aliquoted from larger stocks, and aliquots may be stored either frozen or at room temperature. Larger aliquots of 200-400µl are good for diluting dried or concentrated primer stocks (**Figure 2a**). Smaller aliquots of 10-50 µl are useful for supplementing the volumes of primer combinations 3 and 4. TE is inexpensive and aliquots should be discarded after use.

Multiplex enzyme kits are quite expensive and should be kept frozen (-20°C) until use. Following PCR preparation, any unused multiplex solutions should be returned immediately to 4°C. The small Qiagen Multiplex PCR Kit comes with 3 tubes of multiplex mix, each containing 0.85ml (850µl) of solution; enough for about 65-70 PCRs.

Generally, it is best to avoid repeated, major temperature changes for the materials used in this type of laboratory work including the DNA samples, primers and multiplex kit solutions. All materials should be stored at -20°C until needed, and then kept at 4°C until consumed. Long term storage of DNA should be at -80°C.

All materials containing spent tissue, primers and/or DNA should be autoclaved and disposed of when no longer of any use. All samples treated with ethidium bromide or formamide should be treated as hazardous waste and disposed in accordance with the institution's hazardous materials policy.

VNTR Multiplex PCR Combination	Locus	Allele amplicon repeats NHDP63 ^a	NHDP63 amplicon size (bp)
1	(AC)8b	7	384
	(GTA)9	10	307
	(GGT)5	4	239
	(AT)17	13	175
	6-3a (rpoT)	3	89
2	21-3	2	290
	ML1 (52-2) ^b	1	214
	(AC)9	8	207
	(AT)15	16	172
	(AC)8a	10	125
3	27-5	4	301
	6-7	7	264
	(TA)18	16	224
	(TTC)21	10	170
4	18-8	8	346
	12-5	5	287
	23-3	2	219
	(TA)10	13	192

^a NHDP63 reference isolate, Kimura *et al.*¹⁰ JCM 2009

^b Manuscript in preparation, Li *et al.*, 2011

Table 1: Amplicon sizes for strain NHDP63

Cycling Parameters		
PCR Protocol Name: ML VNTR MPCR		
# of cycles:		
Steps	Temperature -Time	
Initiation activation step	95°C for 15 min	
Denaturation	94°C for 30 sec	
Annealing	60°C for 90 sec	Repeat 40 cycles
Extension	72°C for 90 sec	
Final Extension	72°C for 10 min	
Start Time:	End Time:	

Table 2: Cycling Parameters for VNTR PCR

Components	Volume/ Reaction (µl)	# of test samples	Volume used in Mastermix (µl)	Completion Checkbox
Qiagen® Multiplex PCR Mix (2X)	12*			<input type="checkbox"/>
UPPER Primer Mix (2µM)	2			<input type="checkbox"/>
LOWER Primer Mix (2µM)	2			<input type="checkbox"/>
Q Solution	2			<input type="checkbox"/>
Aliquot 18µl to each PCR tube				<input type="checkbox"/>
Add 2µl DNA template to each tube				<input type="checkbox"/>
Total Volume	20			

Important: when determining the # of samples, always account for 1x positive control and 1x negative control. Add 1-2 extra sample volumes to allow for pipetting losses if you have more than 5 samples.

*Excess Multiplex is used to avoid having to add water or TE to bring to 20µl.

Table 3: Preparation of PCR

Use GS500(-250)LIZ as the sizing standard for analysis.

(AC) 8b	(GTA) 9	(GGT) 5	(AT) 17	rpoT (6-3a)
382 (6)	294-5 (6)	239 (4)		89-90 (3)
384 (7)	297-8 (7)	242 (5)	169 (10)	95-6 (4)
386 (8)	301-2 (8)	245 (6)	171 (11)	
388 (9)	304-5 (9)		173 (12)	
	~307 (10)		175 (13)	
	310 (11)		177 (14)	
	313 (12)		179 (15)	
	316 (13)		181 (16)	
	319 (14)		183 (17)	
	322 (15)		185 (18)	
	325 (16)		187 (19)	
	328 (17)		189 (20)	
	331 (18)		191 (21)	
	333 (19)			
Indicates NHDP63 Positive control number of tandem repeats				

(AC)8b Green peak. Ignore single green spike at 216.
 (GTA)9 Black peak. (GGT)5 Blue peak. (AT)17 Red peak.
 rpoT (6-3a) Green peak.

Table 4: Allele Calls for Combination 1

Combination 2				
21-3	ML 1	(AC) 9	(AT) 15	(AC) 8a
269 (1)	214 (1)	203-4 (6)	166 (13)	121 (8)
290 (2)	266 (2)	205-6 (7)	168 (14)	123 (9)
311-12 (3)		207-8 (8)	170 (15)	125 (10)
332-3 (4)		209 (9)	172-3 (16)	
		211 (10)	174 (17)	
		213 (11)	176 (18)	
			178 (19)	
			180 (20)	
			182 (21)	
			184 (22)	
			186 (23)	
			188 (24)	
Indicates NHDP63 Positive control number of tandem repeats				

21-3 Blue peak. ML 1 Green peak. (AC)9 Black peak.
 (AT)15 Family of red peaks. (AC)8a Green peak.

Table 5: Allele Calls for Combination 2

27-5	6-7	(TA) 18	(TTC) 21
274 (3)	252 (5)	216 (12)	169-170 (10)
301 (4)	258 (6)	218 (13)	172-3 (11)
329 (5)	264 (7)	220 (14)	175-6 (12)
	270 (8)	222 (15)	178-9 (13)
	276 (9)	~224.5 (16)	181-2 (14)
		226 (17)	184-5 (15)
		228 (18)	187-8 (16)
		230 (19)	190-1 (17)
		232 (20)	193-4 (18)
		234 (21)	196-7 (19)
		236 (22)	199-200 (20)
			202-3 (21)
		Ignore human 242	205-6 (22)
			208-9 (23)
			211-12 (24)
			214-15 (25)
			217-18 (26)
			220-1 (27)
			223-4 (28)
Indicates NHDP63 Positive control number of tandem repeats			

27-5 Blue peak. 6-7 Green peak. (TA)18 Black peak. Ignore black at 242 (human). (TTC) 21 Red peak.

Table 6: Allele Calls for Combination 3

18-8	12-5	23-3	(TA) 10
	263 (3)	197 (1)	180 (7)
256 (3)	275 (4)	219 (2)	182 (8)
274 (4)	287 (5)	242 (3)	184 (9)
292 (5)			186 (10)
310 (6)			188 (11)
328 (7)			190 (12)
346 (8)			192 (13)
364 (9)			194 (14)
382 (10)			
400 (11)			
Indicates NHDP63 Positive control number of tandem repeats			

18-8 Red peak. It may help to deselect the other peak colors.
12-5 Green peak. 23-3 Blue peak. (TA)10 Family of red peak.

Table 7: Allele Calls for Combination 4




Figure 1: VNTR-FLA Process Flow Diagram





Figure 2. (a) Preparation of Combination 1 Upper Primers (Eppendorf tube picture courtesy of www.clker.com). (b) PCR Setup (for 8 PCRs) (Eppendorf tube picture courtesy of www.clker.com)



L = 20 base pair molecular ladder
 1-8 = patient samples
 NC = negative control (TE buffer)
 PC = NHDP63 strain positive control

Figure 3. Agarose gel of Combinations 1 and 2 VNTR PCR product DNA

A) Example plate map for FLA using an 8 X 12, 96-well plate.

	01	02	03	04	05	06	07	08	09	10	11	12
	C1	C2	C3	C4	C1	C2	C3	C4	C1			
A	B292	B292	B292	B292	B298	B298	B298	B298	Blank			
	C1	C2	C3	C4	C1	C2	C3	C4	C2			
B	B293	B293	B293	B293	B299	B299	B299	B299	Blank			
	C1	C2	C3	C4	C1	C2	C3	C4	C3			
C	B294	B294	B294	B294	B300	B300	B300	B300	Blank			
	C1	C2	C3	C4	C1	C2	C3	C4	C4			
D	B295	B295	B295	B295	B301	B301	B301	B301	Blank			
	C1	C2	C3	C4	C1	C2	C3	C4				
E	B296	B296	B296	B296	B302	B302	B302	B302				
	C1	C2	C3	C4	C1	C2	C3	C4				
F	B297	B297	B297	B297	B303	B303	B303	B303				
	C1	C2	C3	C4	C1	C2	C3	C4				
G	NC	NC	NC	NC	B304	B304	B304	B304				
	C1	C2	C3	C4	C1	C2	C3	C4				
H	PC	PC	PC	PC	B305	B305	B305	B305				

C1 = Primer Combination 1, etc. B292 = Patient sample number
 PC = Positive Control, NC = Negative Control, Blank = Extraction Blank

B)


Name	Date modified	Type	Size
Vissa100921RR	10/6/2010 9:25 AM	File folder	
C1_B292_A01.fsa	9/21/2010 6:30 PM	FSA File	92 KB
C1_B292R_A05.fsa	9/21/2010 7:56 PM	FSA File	91 KB
C1_B293_B01.fsa	9/21/2010 6:30 PM	FSA File	92 KB
C1_B294_C01.fsa	9/21/2010 6:30 PM	FSA File	92 KB
C1_B295_D01.fsa	9/21/2010 6:30 PM	FSA File	92 KB
C1_B296_E01.fsa	9/21/2010 6:30 PM	FSA File	92 KB
C1_B297_F01.fsa	9/21/2010 6:30 PM	FSA File	92 KB
C1_B298_A06.fsa	9/21/2010 7:56 PM	FSA File	91 KB
C1_B299_B06.fsa	9/21/2010 7:56 PM	FSA File	91 KB
C1_B300_C06.fsa	9/21/2010 7:56 PM	FSA File	91 KB
C1_B301_D06.fsa	9/21/2010 7:56 PM	FSA File	91 KB
C1_B302_E06.fsa	9/21/2010 7:56 PM	FSA File	91 KB
C1_B303_F06.fsa	9/21/2010 7:56 PM	FSA File	91 KB
C1_B304_G06.fsa	9/21/2010 7:56 PM	FSA File	91 KB
C1_NC_G01.fsa	9/21/2010 6:30 PM	FSA File	92 KB
C1_NC2_A10.fsa	9/21/2010 9:22 PM	FSA File	91 KB
C1_PC_H01.fsa	9/21/2010 6:30 PM	FSA File	92 KB
C1_PC_H06.fsa	9/21/2010 7:56 PM	FSA File	90 KB
C2_B292_A02.fsa	9/21/2010 6:30 PM	FSA File	91 KB
C2_B293_B02.fsa	9/21/2010 6:30 PM	FSA File	91 KB
C2_B293R_B05.fsa	9/21/2010 7:56 PM	FSA File	91 KB
C2_B294_C02.fsa	9/21/2010 6:30 PM	FSA File	92 KB
C2_B294R_C05.fsa	9/21/2010 7:56 PM	FSA File	90 KB
C2_B295_D02.fsa	9/21/2010 6:30 PM	FSA File	92 KB
C2_B295R_D05.fsa	9/21/2010 7:56 PM	FSA File	90 KB
C2_B296_E02.fsa	9/21/2010 6:30 PM	FSA File	91 KB
C2_B297_F02.fsa	9/21/2010 6:30 PM	FSA File	92 KB
C2_B298_A07.fsa	9/21/2010 8:39 PM	FSA File	91 KB
C2_B299_B07.fsa	9/21/2010 8:39 PM	FSA File	91 KB
C2_B300_C07.fsa	9/21/2010 8:39 PM	FSA File	91 KB
C2_B301_D07.fsa	9/21/2010 8:39 PM	FSA File	91 KB
C2_B302_E07.fsa	9/21/2010 8:39 PM	FSA File	91 KB

10:6:30 PM Date created: 10/6/2010 9:24 AM

Sample .fsa files.

These files may be loaded into Peak Scanner software for analysis.

Figure 4. (a) FLA Plate Map. (b) FLA data files: *.fsa



Orange peaks are the sizing standards (GS 500LIZ).

Each colored peak (or family of peaks- green, red, blue or black) represents a bacterial DNA amplicon for a VNTR locus.

The height of a peak and its size (in base pairs) is revealed by clicking on the peak and is shown in a box on the x-axis. (Figure 5b)

Here, rpoT (green) = 89 bp, (AT)17 (red) = 175 bp, (GGT)5 (blue) = 238 bp, (GTA)9 (black) = 307 bp, and (AC)8b (green) = 384 bp.

These are all of the expected sizes in base pairs for NHDP63.






Figure 5. (a) FLA Chromatogram of Positive Control (NHDP63) for Combination 1 VNTR loci. (b) Peak Scanner data for amplicon size and abundance of (GTA)9




No. of tandem repeats of (GTA): 9 copies 10 copies 11 copies
Figure 6. Comparison of PCR samples to the PC (NHDP63) for locus (GTA)9




Because (TA)₁₀ is a 2 bp repeat (TA), stutter peaks are 2 bp shorter or longer than the main peak. Main peak: 190 bp, -1 Stutter peak: 188 bp, -2 stutter peak: 186 bp, +1 stutter peak: 192 bp.

Figure 7. Main and Stutter Peaks for (TA)₁₀




(AT)₁₅ Primer and PCR strand



Main DNA strand

(AT)₁₅ Primer and PCR strand



Main DNA strand

Figure 8: +A (A-tail) Peaks Adjacent to Main or Stutter Peaks.




Figure 9: (TA)18 Main Peak, Stutter Peaks and Human DNA Peak

A)

	Patient	Loci			
		(AC)8b	(GGT)5	27-5	12-5
Country A	1	7	4	4	5
	2	7	4	4	5
	3	7	4	4	5
	4	7	4	4	5
	5	7	4	4	5
	6	7	4	4	5
Country B	7	7	4	5	3
	8	7	4	5	3
	9	7	4	5	3
	10	7	4	5	3
	11	7	4	5	3
	12	7	4	5	3
	13	7	4	5	3
Country C	14	8	4	5	4
	15	8	4	5	4
	16	8	4	5	4
	17	8	4	5	4
	18	8	4	5	4
	19	8	4	5	4
	20	8	4	5	4

Note that examining only 1 or 2 loci, such as (AC)8b and (GGT)5 does little to distinguish bacterial strains even between large geographic regions, such as countries. But adding more loci, may produce a more unique DNA fingerprint for differing strains of *M. leprae*. For the loci (AC)8b, (GGT)5, 27-5 and 12-5, each country shows a unique combination of VNTRs: Country A: 7, 4, 4, 5; Country B: 7, 4, 5, 3; and Country C: 8, 4, 5, 4.

B)

Family	Patient	Loci											
		(AC)8b	(GTA)9	(GGT)5	(AT)17	21-3	(AC)9	(AT)15	(AC)8a	6-7	18-8	12-5	(TA)10
A	1	6	9	4	18	1	9	15	9	6	7	4	10
	2	6	9	4	19	1	9	15	8	8	7	4	10
	3	7	9	6	15	3	9	13	9	8	8	4	13
B	4	9	9	5	15	3	9	14	9	7	8	5	13
	5	9	9	5	15	3	9	14	9	7	8	5	13
	6	8	9	5	15	3	9	14	9	7	8	5	11
C	7	8	9	5	15	3	9	14	9	7	8	5	11

By examining more loci, especially those with greater allele variability (polymorphism) it is possible to distinguish bacterial strain types to a much greater degree. Differences appear between regions of the same country and even within the same city or town.

Here, we see 3 families from the same village. It appears that the two members of Family A are likely infected with the same strain of *M. leprae*, but distinguishable from that of Families B and C. Families B and C appear to be infected with closely related strains.

It even appears that Family member B-3 (in red) has a different strain of the bacterium than the other members of the same family.

It becomes possible to trace sources of infection and identify at-risk individuals using VNTR-FLA.

Figure 10: (A) Strain Differentiation of *M. leprae* based on VNTR data. **(B)** Strain Differentiation of *M. leprae* based on MLVA DNA Fingerprint

Discussion

The collection of skin samples from leprosy patients requires skilled clinicians or technicians working at skin clinics. Laboratory workers handling these samples must take great care to wear lab coats, gloves and protective eye wear and to work in a bio-safety cabinet when handling infected samples of human or armadillo tissue. Disinfection of surfaces and tools is also critical. Working in a clean, sterile bio-safe cabinet is important for avoiding contamination of DNA samples.

DNA extraction has become relatively easy thanks to the development of extraction kits from companies like Qiagen. Directions must be followed carefully. All samples should be kept cold when not in use. Avoid repeated, extreme temperature changes for samples.

DNA primers used in this work can be ordered from various companies which have been cited in the list of literature references at the end of this paper. Care should be taken to work with primers in a DNA free environment in order to avoid contamination. Primers come as dry powder and must be mixed with TE and diluted to a 100µM concentration, then separated into smaller quantities (**Figure 2a**). Working solutions of primers are further diluted to 10µM concentrations. Again, do not use DNA samples in areas/hoods where primers are used and prepared.

PCR products should also be kept cold when not in use.

A 3% agarose gel preparation will give better DNA band separation, but takes longer to run. For purely qualitative purposes, 2% is usually sufficient. Ethidium bromide solution used for staining the DNA in agarose gels is a highly active genotoxin that is absorbed through the skin. Handle this solution and gels stained with it using great care and always being sure to wear gloves. Wash hands thoroughly after handling any DNA samples or ethidium bromide materials. Dispose of ethidium bromide staining solution, wash and gels according to institutional guidelines. Gels are not routinely required; this step can be eliminated once FLA methods have been established. It is time and reagent consuming.

The formamide solution used in preparing samples for FLA is also highly toxic and should be handled with care. Wash hands after its use. Dispose of it following institutional guidelines.

Reading the results of FLA using *Peak Scanner* software can be challenging. A basic set of allele calls (number of tandem repeats) has been developed at CSU (**Tables 4-7**). (It should be noted that **Tables 4-7** may not be all inclusive. As other strains of *M. leprae* are studied, alleles with copy numbers outside the ranges listed may be found.) One particular challenge involves 'stutter' peaks. These are families of peaks, especially of STRs that only involve 2-3 base pair repeats, such as (TA)10. Sometimes selecting the correct peak to read is difficult (**Figure 7**). In this figure, the peak in the positive control at 190 bp is the main peak. Peaks lower in height that are 2, 4, or even 6 base pairs larger or smaller than the main peak are called 'stutter peaks.' A-tailing can also cause confusion. A-tailing is described earlier in the text and in **Figure 8**. Finally, if PCR products are highly abundant in the samples, peaks may appear with a double spike. In this case, read the center of the peak form. (See **Figure 6**, Patient 6.)

Data management can be a formidable task for this type of work. It is important to record all pertinent information for all experiments such as: date of a task or procedure, operator, strip/plate maps, FLA orders, PCR conditions and recipes, dates of gels and photographs, storage temperatures, DNA template dilutions, FLA electronic file storage locations, etc. Good organization and data management can save hours of time spent looking for specific pieces of information in the future.

The laboratory work described here has been going on for several years at Colorado State University and at other locations around the world. The large picture of what all of the collected data means and how it may be of future use is beginning to emerge. **Figures 10A and 10B**

demonstrate how these DNA fingerprints can be used to distinguish different *M. leprae* strains between countries (10A) or even between families (10B). Family and community linked cases have been shown to carry *M. leprae* of similar or identical VNTR strain types. The hope is that it may be possible to gain further insight into the mode(s) of leprosy transmission so that an early detection system of transmission networks may be developed for those people most at risk, and that curative drug therapy may begin before permanent neurological and dermatological damage is done.

Disclosures

No conflicts of interest declared.

Acknowledgements

Funding was provided by NIH/NIAID grant RO1-AI-63457 and ARRA grant supplement RO1-AI-63457 S1. We acknowledge the contributions of all current and past members of the laboratory group and collaborators.

References

1. World Health Organization. Chemotherapy of leprosy for control programmes. *Technical Report Series*. **675**, 18-22. (1982)
2. World Health Organization. W. H. O. Leprosy Elimination: Leprosy Today [Online] <http://www.who.int/lep/en/> (2010).
3. Cole, S. T., *et al.* Massive gene decay in the leprosy bacillus. *Nature*. **409**, 1007-1011 (2001).
4. Leproma web server: [online] <http://genolist.pasteur.fr/Leproma/>.
5. Groathouse, N. A., *et al.* Multiple Polymorphic Loci for Molecular Typing of Strains of *Mycobacterium leprae*. *J. of Clinical Microbiology*. **42** (4), 1666-72 (2004)
6. Zhang, L., *et al.* Diversity of Potential Short Tandem Repeats in *Mycobacterium leprae* and Application for Molecular Typing. *J. of Clinical Microbiology*. **43**, 10. 5221-29. (2005)
7. Young, S. K., *et al.* Microsatellite Mapping of *Mycobacterium leprae* Populations in Infected Humans. *J. of Clinical Microbiology*. **42** (11), 4931-36 (2004).
8. Young, S. K., *et al.* Use of Short Tandem Repeat Sequences to Study *Mycobacterium leprae* in Leprosy Patients in Malawi and India. *Public Library of Science: Neglected Tropical Diseases*. **2**, 4. E214 [online] www.plosntds.org/article/info%3Adoi%2F10.1371%2Fjournal.pntd.0000214 (2008).
9. Monot, M., *et al.* Are Variable-Number Tandem Repeats Appropriate for Genotyping *Mycobacterium leprae*? *J. of Clinical Microbiology*. **46** (7), 2291-97 (2008).
10. Kimura, M., *et al.* Rapid Variable Number Tandem-Repeat Genotyping for *Mycobacterium leprae* Clinical Specimens. *J. of Clinical Microbiology*. **47** (6), 1757-66 (2009).
11. Xiaoman Weng, *et al.* Identification and Distribution of *Mycobacterium leprae* Genotypes in a Region of High Leprosy Prevalence in China: a 3-Year Molecular Epidemiological Study. *J. of Clinical Microbiology*. **45** (6), 1728-34 (2007).
12. Weng, X., *et al.* Transmission of leprosy in Qiubei County, Yunnan, China: Insights from an eight year molecular epidemiology investigation. *Infection, Genetics and Evolution*. [Online] <http://www.ncbi.nlm.nih.gov/pubmed/21129505> (2010).
13. Sakamuri, R. M., *et al.* Population-Based Molecular Epidemiology of Leprosy in Cebu, Philippines. *J. of Clinical Microbiology*. **47** (9), 2844-54 (2009).
14. Fontes, A. N. B., *et al.* Genetic diversity of *Mycobacterium leprae* isolates from Brazilian leprosy patients. *Leprosy Review*. **80**, 302-315 (2009).